Memphasys Ltd - Asset Resilience Ratio
Memphasys Ltd (MEM) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Memphasys Ltd's Asset Resilience Ratio has changed over time. Check MEM PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Memphasys Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Memphasys Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Memphasys Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Memphasys Ltd Industry Peers by Asset Resilience Ratio
Compare Memphasys Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Memphasys Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Memphasys Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$12.43 Million ≈ $8.80 Million |
-- |
| 2023-06-30 | 0.29% | AU$42.75K ≈ $30.25K |
AU$14.67 Million ≈ $10.38 Million |
-4.49pp |
| 2018-06-30 | 4.79% | AU$201.81K ≈ $142.79K |
AU$4.22 Million ≈ $2.98 Million |
-47.63pp |
| 2017-06-30 | 52.42% | AU$3.83 Million ≈ $2.71 Million |
AU$7.30 Million ≈ $5.17 Million |
+51.82pp |
| 2016-06-30 | 0.59% | AU$42.74K ≈ $30.24K |
AU$7.19 Million ≈ $5.09 Million |
+0.04pp |
| 2015-06-30 | 0.56% | AU$38.00K ≈ $26.89K |
AU$6.84 Million ≈ $4.84 Million |
-- |
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more